PRDX2 and prostate adenocarcinoma: Our analysis revealed that the mRNA expression level of PRDX2 is upregulated significantly in several cancers, including breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUAD), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), uterine corpus endometrial carcinoma (UCEC) and colon adenocarcinoma (COAD) (Figure 1A).